Register Login
Register to leave comments
  • News bot April 6, 2026, 8:24 p.m.

    📋 PRAXIS PRECISION MEDICINES, INC. (PRAX) - Clinical Trial Update

    Filing Date: 2026-04-06

    Accepted: 2026-04-06 16:23:42

    Event Type: Clinical Trial Update

    Event Details:

    PRAXIS PRECISION MEDICINES, INC. (PRAX) Announces Clinical Trial Update PRAXIS PRECISION MEDICINES, INC. (PRAX) provided an update on its clinical development programs. Clinical Development Highlights: Clinical development progress update.

    🔬 Clinical Development Pipeline (PRAXIS PRECISION MEDICINES, INC.):

    Product Type Development Stage Therapeutic Area Source
    sham procedure PROCEDURE Phase PHASE3 Epileptic Encephalopathy ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Focal Epilepsy ClinicalTrials.gov
    20 mg/day vormatrogine for 12 weeks DRUG Phase PHASE3 Focal Epilepsy ClinicalTrials.gov
    30 mg/day vormatrogine for 12 weeks DRUG Phase PHASE3 Focal Epilepsy ClinicalTrials.gov
    40 mg/day vormatrogine for 12 weeks DRUG Phase PHASE3 Focal Epilepsy ClinicalTrials.gov
    3D1002 + OxyContin (Phase IIb) DRUG Phase PHASE2 Cancer Pain ClinicalTrials.gov
    OxyContin monotherapy (Phase IIb) DRUG Phase PHASE2 Cancer Pain ClinicalTrials.gov
    3D1002 monotherapy (Phase IIb) DRUG Phase PHASE2 Cancer Pain ClinicalTrials.gov
    3D1002 (150 mg)(Phase IIa) DRUG Phase PHASE2 Cancer Pain ClinicalTrials.gov
    3D1002 (100 mg)(Phase IIa) DRUG Phase PHASE2 Cancer Pain ClinicalTrials.gov
    3D1002 (50 mg)(Phase IIa) DRUG Phase PHASE2 Cancer Pain ClinicalTrials.gov
    vormatrogine DRUG Phase PHASE3 Epilepsy, Tonic-Clonic ClinicalTrials.gov
    TYK-01054 DRUG Phase PHASE1 Solid Tumor Malignancies ClinicalTrials.gov
    Anlotinib DRUG Approved Non-Small Cell Lung Cancer ClinicalTrials.gov
    60 mg PRAX-114 DRUG Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    20 mg PRAX-114 DRUG Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    10 mg PRAX-114 DRUG Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    3D229 DRUG Phase PHASE1 Healthy Subject ClinicalTrials.gov
    PRAX-114 DRUG Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    e-learning toolkit BEHAVIORAL Approved Mood Disorders ClinicalTrials.gov
    Virtual implementation protocol BEHAVIORAL Approved Mood Disorders ClinicalTrials.gov
    10 mg PRAX-114 or 20 mg PRAX-114 DRUG Phase PHASE2 Essential Tremor ClinicalTrials.gov
    10 mg PRAX-114, 20 mg PRAX-114, and Placebo DRUG Phase PHASE2 Essential Tremor ClinicalTrials.gov
    40 mg PRAX-114 DRUG Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    60 mg PRAX-114 or 40 mg PRAX-114 DRUG Phase PHASE2 Post-traumatic Stress Disorder ClinicalTrials.gov
    Part B: 120 mg PRAX-944 and Placebo DRUG Phase PHASE2 Essential Tremor ClinicalTrials.gov
    Part B: 120 mg PRAX-944 DRUG Phase PHASE2 Essential Tremor ClinicalTrials.gov
    Part A: 20 and 40 mg PRAX-944 DRUG Phase PHASE2 Essential Tremor ClinicalTrials.gov
    Flexibly dosed 20 mg to 100 mg PRAX-944 DRUG Phase PHASE2 Essential Tremor ClinicalTrials.gov
    60 mg PRAX-944 DRUG Phase PHASE2 Essential Tremor ClinicalTrials.gov
    100 mg PRAX-944 DRUG Phase PHASE2 Essential Tremor ClinicalTrials.gov
    60 mg ulixacaltamide DRUG Phase PHASE3 Essential Tremor ClinicalTrials.gov
    30mg PRAX-628 DRUG Phase PHASE2 Focal Onset Seizure ClinicalTrials.gov
    20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks DRUG Phase PHASE2 Focal Seizure ClinicalTrials.gov
    PRAX-628 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    PRAX-562 DRUG Phase PHASE2 SCN2A Encephalopathy ClinicalTrials.gov
    1.5mg/kg/day PRAX-562 DRUG Phase PHASE3 Developmental and Epileptic Encephalopathy 1 ClinicalTrials.gov
    1.0mg/kg/day PRAX-562 DRUG Phase PHASE3 Developmental and Epileptic Encephalopathy 1 ClinicalTrials.gov
    0.5mg elsunersen DRUG Phase PHASE3 Epileptic Encephalopathy ClinicalTrials.gov
    1mg elsunersen DRUG Phase PHASE3 Epileptic Encephalopathy ClinicalTrials.gov
    PRAX-222 - Fixed Doses DRUG Phase PHASE1 SCN2A-DEE ClinicalTrials.gov
    PRAX-222 - Optional Ascending Doses DRUG Phase PHASE1 SCN2A-DEE ClinicalTrials.gov
    PRAX-222 - Initial Ascending Doses DRUG Phase PHASE1 SCN2A-DEE ClinicalTrials.gov
    PRAX-222 - Initial Dose DRUG Phase PHASE1 SCN2A-DEE ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: PRAXIS PRECISION MEDICINES, INC.
    • Ticker Symbol: PRAX

Search

News categories